MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
1.825
-0.105
-5.44%
Opening 10:34 05/13 EDT
OPEN
1.980
PREV CLOSE
1.930
HIGH
1.980
LOW
1.820
VOLUME
5.14M
TURNOVER
--
52 WEEK HIGH
12.51
52 WEEK LOW
1.650
MARKET CAP
609.43M
P/E (TTM)
-1.4792
1D
5D
1M
3M
1Y
5Y
1D
Iovance Biotherapeutics Price Target Cut to $8.00/Share From $16.00 by Goldman Sachs
Dow Jones · 21h ago
Iovance Biotherapeutics Is Maintained at Buy by Goldman Sachs
Dow Jones · 21h ago
Goldman Sachs Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $8
Benzinga · 21h ago
Iovance Biotherapeutics Price Target Cut to $10.00/Share From $30.00 by Mizuho
Dow Jones · 23h ago
Iovance Biotherapeutics Is Maintained at Outperform by Mizuho
Dow Jones · 23h ago
Mizuho Maintains Outperform on Iovance Biotherapeutics, Lowers Price Target to $10
Benzinga · 23h ago
Iovance Biotherapeutics Price Target Cut to $4.00/Share From $5.00 by Barclays
Dow Jones · 1d ago
Iovance Biotherapeutics Is Maintained at Overweight by Barclays
Dow Jones · 1d ago
More
About IOVA
More
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Recently
Symbol
Price
%Change

Webull offers Iovance Biotherapeutics Inc stock information, including NASDAQ: IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.